Sebastian Aguiar, geroscientist and Venture Fellow at Apollo Ventures, delivers the Lord Florey Lecture at Lincoln College, Oxford in November 2018. H...
The chaotic inner life of cancer
(Continued from part I) Most people who’ve meet cancer on the battlefield of treatment, doctors or patients, come away with the impression of a robust...
Glucosamine: The new metformin? | Interview with Dr. Michael Ristow (part ii)
Last week when we heard from Dr. Ristow, he turned the outdated notion of the “free radical theory of aging” on its head, and demonstrated that antiox...
James Peyer: Why primary indications matter
“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs eve...
Research roundup: Tau tangles guilty by association, and more
It looks like those clumps of tau protein that form inside the neurons of Alzheimer’s brains may actually be protective, and the real damage mig...
James Peyer: “The 21st century will be defined by our struggle against the diseases of aging.”
“At what age would you like to get Alzheimer’s?” This was the question posed by venture capitalist, former stem cell biologist and G...
A bountiful harvest of research
Keeping one eye on your calories, and the other on that delicious-looking pumpkin pie? Don’t worry–your Thanksgiving sins probably wonR...
Metformin as Geroprotector
The diabetes drug Metformin is handled as new anti-aging compound. But which studies actually promoted the longevity effects of Metformin? We provide ...
Better together? Testing the first combination therapies for longevity
The normal mode of drug discovery is a pretty singular affair: one compound, one disease. This is enough for many traditional diseases, but when you’r...
In the media: Mouse mugshots, metabolic mayhem and metformin
Is a picture worth a thousand biomarkers? MouseAGE, the AI that wants to eyeball the age of rodents, thinks so. Dr. Craig Thomspon talks cancer metabo...